Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor

[1]  R. Schinazi,et al.  5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens , 2005, Cancer Chemotherapy and Pharmacology.

[2]  Liansheng Liu,et al.  Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease , 2003, Brain Research.

[3]  R. Schinazi,et al.  Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy , 2001, Cancer Chemotherapy and Pharmacology.

[4]  R. Schinazi,et al.  Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy , 2001, Cancer Chemotherapy and Pharmacology.

[5]  R. Schinazi,et al.  5-phenylthioacyclouridine: a potent and specific inhibitor of uridine phosphorylase. , 2000, Biochemical pharmacology.

[6]  O. Ashour,et al.  Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine. , 2000, Biochemical pharmacology.

[7]  E. Chu,et al.  Benzylacyclouridine Enhances 5-Fluorouracil Cytotoxicity against Human Prostate Cancer Cell Lines , 1998, Pharmacology.

[8]  J. Bertino,et al.  Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Schwartz,et al.  A phase I trial of a modified, dose intensive FAMTX regimen (High dose 5‐fluorouracil + doxorubicin + high dose methotrexate + leucovorin) with oral uridine rescue , 1996, Cancer.

[10]  O. Ashour,et al.  5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy. , 1996, Biochemical pharmacology.

[11]  O. Ashour,et al.  Enhancement of 5-fluoro-2'-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside. , 1995, Cancer research.

[12]  F. Naguib,et al.  Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. , 1994, Cancer research.

[13]  G. Peters,et al.  Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil. , 1993, Anticancer research.

[14]  N. Kemeny,et al.  Uridine allows dose escalation of 5‐fluorouracil when given with N‐phosphonacetyl‐L‐Aspartate, methotrexate, and leucovorin , 1993, Cancer.

[15]  S. Soong,et al.  Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. , 1993, Biochemical pharmacology.

[16]  D. Baccanari,et al.  Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine. , 1993, Biochemical pharmacology.

[17]  G. Peters,et al.  Modulation of fluorouracil toxicity with uridine. , 1992, Seminars in oncology.

[18]  W. Gerok,et al.  Uridine catabolism by the isolated perfused rat liver. , 1992, Journal of hepatology.

[19]  C. V. Groeningen,et al.  Clinical relevance of biochemical modulation of 5-fluorouracil , 1991 .

[20]  P. Calabresi,et al.  Tissue-specific expansion of uridine pools in mice. Effects of benzylacyclouridine, dipyridamole and exogenous uridine. , 1991, Biochemical pharmacology.

[21]  G. Peters,et al.  Clinical and pharmacologic study of orally administered uridine. , 1991, Journal of the National Cancer Institute.

[22]  S. Soong,et al.  Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. , 1990, Biochemical pharmacology.

[23]  A. Falcone,et al.  Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice , 1990 .

[24]  R. Diasio,et al.  Advances in Chemotherapy of AIDS , 1990 .

[25]  B. Chabner,et al.  Cancer Chemotherapy: Principles and Practice , 1990 .

[26]  G. Peters,et al.  Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. , 1989, Journal of the National Cancer Institute.

[27]  R. Handschumacher,et al.  Benzylacyclouridine. Pharmacokinetics, metabolism and biochemical effects in mice. , 1988, Biochemical pharmacology.

[28]  G. Peters,et al.  In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil. , 1988, British Journal of Cancer.

[29]  G. Peters,et al.  Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites , 1988, Cancer Chemotherapy and Pharmacology.

[30]  G. Peters,et al.  Effect of Pyrimidine Nucleosides on Body Temperatures of Man and Rabbit in Relation to Pharmacokinetic Data , 1987, Pharmaceutical Research.

[31]  R. Handschumacher,et al.  Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. , 1986, Cancer research.

[32]  H. M. Pinedo,et al.  Clinical and pharmacokinetic studies of prolonged administration of high dose uridine intended for rescue from 5 fluorouracil toxicity , 1986 .

[33]  H. D. Hochstein,et al.  Uridine‐induced hyperthermia in the rabbit , 1986, The Journal of pharmacy and pharmacology.

[34]  Handschumacher Re,et al.  Tissue-specific Enhancement of Uridine Utilization and 5-Fluorouracil Therapy in Mice by Benzylacyclouridine , 1985 .

[35]  J. Pausch,et al.  Uridine catabolism in Kupffer cells, endothelial cells, and hepatocytes. , 1985, European journal of biochemistry.

[36]  G. Peters,et al.  Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. , 1984, Cancer research.

[37]  P. Klubes,et al.  Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. , 1983, Cancer research.

[38]  A. Monks,et al.  Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. , 1983, Biochemical pharmacology.

[39]  S. Spiegelman,et al.  High-dose 5-fluorouracil with delayed uridine "rescue" in mice. , 1982, Cancer research.

[40]  A. Monks,et al.  Uridine regulation by the isolated rat liver: perfusion with an artificial oxygen carrier. , 1982, The American journal of physiology.

[41]  R. Handschumacher,et al.  Novel single-pass exchange of circulating uridine in rat liver. , 1981, Science.

[42]  R. Handschumacher,et al.  Salvage of circulating pyrimidine nucleosides in the rat. , 1981, Cancer research.

[43]  P. Klubes,et al.  Uridine rescue from the lethal toxicity of 5-fluorouracil in mice , 2004, Cancer Chemotherapy and Pharmacology.

[44]  I. Abramson,et al.  Uridine pharmacokinetics in cancer patients , 2004, Cancer Chemotherapy and Pharmacology.

[45]  D. Martin,et al.  Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine , 2004, Cancer Chemotherapy and Pharmacology.

[46]  H. McClure,et al.  Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.

[47]  M. Hidalgo,et al.  Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Schinazi,et al.  Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy , 2000, Cancer Chemotherapy and Pharmacology.

[49]  اسامة عاشور.  Modulation of plasma uridine concentration by 5-(phenylselenenyl) acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy , 2000 .

[50]  G. Peters,et al.  Clinical relevance of biochemical modulation of 5-fluorouracil. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  R. Handschumacher,et al.  Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools. , 1989, Pharmacology & therapeutics.